Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

More than 1,000,000 patients are being treated with Dupixent globally. 1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has ...

Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another ... including weight gain, high blood sugar, and mood changes. The FDA’s review is based on data ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 ...

More than one million patients are being treated with Dupixent globally. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has ...

Regeneron Pharmaceuticals (NASDAQ ... The main reason is the extremely high competition in the PD-1/PD-L1 checkpoint inhibitors market, which includes Merck's Keytruda, Bristol-Myers Squibb's ...

More than 1,000,000 patients are being treated with Dupixent globally. 1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has ...

constipation, upper respiratory tract infection, limb injury, and insomnia, according to Sanofi. The dupilumab studies were funded by Sanofi and Regeneron, the companies co-developing dupilumab.

Dupilumab development program Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical ...